JP3853097B2 - Topical skin preparation - Google Patents

Topical skin preparation Download PDF

Info

Publication number
JP3853097B2
JP3853097B2 JP37114298A JP37114298A JP3853097B2 JP 3853097 B2 JP3853097 B2 JP 3853097B2 JP 37114298 A JP37114298 A JP 37114298A JP 37114298 A JP37114298 A JP 37114298A JP 3853097 B2 JP3853097 B2 JP 3853097B2
Authority
JP
Japan
Prior art keywords
salt
coa
skin
dephospho
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP37114298A
Other languages
Japanese (ja)
Other versions
JP2000191495A (en
Inventor
栄雄 西戸
和弘 三尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lion Corp
Original Assignee
Lion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corp filed Critical Lion Corp
Priority to JP37114298A priority Critical patent/JP3853097B2/en
Publication of JP2000191495A publication Critical patent/JP2000191495A/en
Application granted granted Critical
Publication of JP3853097B2 publication Critical patent/JP3853097B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、しわをはじめとする皮膚の老化を防止し、滑らかでしっとりした肌を与え、安定性が良好な化粧用クリーム及び美容液等の皮膚化粧料等として有用な皮膚外用剤に関する。
【0002】
【従来の技術】
従来において、皮膚刺激性等に問題点がなく、皮膚細胞の活性化、新陳代謝の促進、創傷治癒効果等を有し、皮膚老化防止効果に優れたCoA(補酵素A、コエンザイムA)及びその塩からなる皮膚外用剤が既に知られている(特開昭50−31051号公報)。
【0003】
しかしながら、CoA及びその塩が製剤中で不安定であり、これらを化粧料に配合すると色調劣化等の他の成分に悪影響を及ぼすという問題点があった。
そのため、本願出願人は、その安定化を検討し、CoA及び/又はその塩の酸化反応により合成した酸化型CoAが製剤中で高い安定性を示し、創傷治癒効果及び小じわ、肌のつや・きめ等の改善効果を有する皮膚外用剤を出願している(特開平2−49729号公報、特許第2781982号)。
【0004】
しかしながら、従来の酸化型CoA及び/又はその塩を配合した皮膚外用剤は、製剤中で安定性を示し、創傷治癒効果及び小じわ、肌のつや・きめ等の改善効果を有する点で優れたものであるが、今日の更なる消費者等の高い要求等に対しては、しわ改善、創傷治癒作用が未だ満足のいくものではなく、また、人の肌に塗布し、実使用に供したときにはその安定性も未だ満足のいくものではないというのが現状である。
【0006】
【発明が解決しようとする課題】
本発明は、上記従来技術の課題等に鑑み、これを解消しようとするものであり、今日の更なる消費者等の高い要求等に対して、しわをはじめとする皮膚の老化を防止し、滑らかでしっとりした肌を与え、安定性が更に良好な化粧用クリーム及び美容液等の皮膚化粧料等として有用な皮膚外用剤を提供することを目的とする。
【0007】
【課題を解決するための手段】
本発明者らは、上記従来の課題について鋭意検討を重ねた結果、特定種のCoA及び/又はその塩を併用することにより、しわ改善、創傷治癒作用が大きく亢進し、人の肌に塗布し実使用に供したときの酸化型CoA及び/又はその塩の安定性が大きく亢進されることを知見し、上記目的の皮膚外用剤を得ることに成功し、本発明を完成するに至ったのである。
すなわち、本発明の皮膚外用剤は、(A)下記一般式(I)で表される酸化型CoA及び/又はその塩から選ばれる少なくとも1種と、(B)下記一般式(II)−1で表されるデホスホCoA及び/又はその塩、または、下記一般式(II)−2で表されるデホスホCoA誘導体及び/又はその塩から選ばれる少なくとも1種とを含有することを特徴とする皮膚外用剤。
【化1】

Figure 0003853097
【化2】
Figure 0003853097
【化3】
Figure 0003853097
〔上記一般式(II)−2中のRは、デホスホCoA、4’−ホスホパンテテイン、4’−ホスホパントテノイルシステイン、パンテテイン、パントテノイルシステイン、β-アレテイン、システアミン、システイン、グルタチオンを示す。〕」
【0008】
【発明の実施の形態】
以下に、本発明の実施形態を詳しく説明する。
本発明の皮膚外用剤は、(A)下記一般式(I)で表される酸化型CoA及び/又はその塩から選ばれる少なくとも1種と、(B)下記一般式(II)−1で表されるデホスホCoA及び/又はその塩、または、下記一般式(II)−2で表されるデホスホCoA誘導体及び/又はその塩から選ばれる少なくとも1種とを含有することを特徴とするものである。
【化1】
Figure 0003853097
【化2】
Figure 0003853097
【化3】
Figure 0003853097
〔上記一般式(II)−2中のRは、デホスホCoA、4’−ホスホパンテテイン、4’−ホスホパントテノイルシステイン、パンテテイン、パントテノイルシステイン、β-アレテイン、システアミン、システイン、グルタチオンを示す。〕」
【0009】
本発明で用いる(A)成分の酸化型CoAは、下記一般式(I)で表されるものであり、その塩としては、リン酸基部の金属塩を形成するナトリウム塩、リチウム塩、カリウム塩、カルシウム塩、マグネシウム塩、亜鉛塩等の金属塩が挙げられる。
具体的には、酸化型CoAの二ナトリウム塩、四ナトリウム塩、六ナトリウム塩、六カリウム塩、四リチウム塩、六リチウム塩、二カルシウム塩、二マグネシウム塩、二亜鉛塩などが例示される。
これらの酸化型CoA又はその塩は、単独で、または2種以上を混合して使用することができる。
【0010】
【化1】
Figure 0003853097
【0011】
本発明で用いる(B)成分のデホスホCoAは、下記一般式(II)−1で表されるものであり、その塩としては、リン酸基部の金属塩を形成するナトリウム塩、リチウム塩、カリウム塩、カルシウム塩、マグネシウム塩、亜鉛塩等の金属塩が挙げられる。
具体的には、デホスホCoAの五ナトリウム塩、五カリウム塩、五リチウム塩、五カルシウム塩、五マグネシウム塩、五亜鉛塩などが例示される。
これらのデホスホCoA又はその塩は、単独で、または2種以上を混合して使用することができる。
【0012】
【化2】
Figure 0003853097
【0013】
また、(B)成分のデホスホCoA誘導体は、下記一般式(II)−2で表されるものであり、その塩としては、リン酸基部の金属塩を形成するナトリウム塩、リチウム塩、カリウム塩、カルシウム塩、マグネシウム塩、亜鉛塩等の金属塩が挙げられる。
具体的には、デホスホCoA誘導体の五ナトリウム塩、五カリウム塩、五リチウム塩、五カルシウム塩、五マグネシウム塩、五亜鉛塩などが例示される。これらのデホスホCoA誘導体又はその塩は、単独で、または2種以上を混合して使用することができる。
デホスホCoA誘導体としては、下記一般式(II)−2中のRとして、デホスホCoAの他、4’−ホスホパンテテイン、4’−ホスホパントテノイルシステイン、パンテテイン、パントテノイルシステイン、β-アレテイン、システアミン、システイン、グルタチオンが挙げられるが、その中では特にデホスホCoAが望ましい。
【0014】
【化3】
Figure 0003853097
【0015】
本発明の皮膚外用剤において、(A)成分の酸化型CoAの含有量は、皮膚外用剤全量に対して、0.001〜5重量%(以下、%と略称する。)、好ましくは0.01〜2%含有させるのが望ましい。
(A)成分の酸化型CoAの含有量が0.001%未満であると、皮膚の老化防止効果が満足に得られない場合がある。また、5%を超えても通常、それ以上の効果は発揮されず、経済的でない。
一方、(B)成分のデホスホCoA及び/又はその塩、またはデホスホCoA誘導体及び/又はその塩の合計含有量は、皮膚外用剤全量に対して、0.000001%〜5%の範囲で任意の量で添加することが可能である。
(B)成分の合計含有量が0.000001%未満であると、満足な皮膚の老化防止効果と、実使用時における(A)成分の製剤中での安定性効果が発揮されない場合があり、また、5%を超えても通常、それ以上の効果は発揮されず、経済的でない。
【0016】
また、上記(A)成分/(B)成分の比率(重量比)は、特に好ましくは、後述する各実施例となる比率で配合することが望ましい。
【0017】
本発明の皮膚外用剤には、上記(A)成分及び(B)成分の他に、本発明の効果を損なわない範囲で、油分、水、界面活性剤、保湿剤、植物抽出物、低級アルコール、多価アルコール、高級アルコール、粘土鉱物、増粘剤、酸化防止剤、キレート剤、pH調製剤、防腐剤、香料、色素、紫外線吸収剤、紫外線散乱剤、ビタミン類、アミノ酸類、水等通常化粧料、石鹸浴用剤等に用いられる原料(任意成分)を配合することができる。
【0018】
本発明の皮膚外用剤としては、各種化粧用クリーム、スキンミルク(乳液)、ローション(化粧水)、美容液、パック剤、ジェル剤、パウダー、リップクリーム、口紅、アンダーメークアップ、ファンデーション、サンケア、浴用剤、ボディシャンプー、ボディリンス、石けん、クレンジングフォーム、軟膏、ゼリー剤、エアゾール剤等、種々の製品形態が挙げられるが、これらに限定されるものではない。
これらの製品は、本発明における上記(A)成分及び(B)成分と上記任意成分とを常法により適宜配合することにより製造することができる。
【0019】
このように構成される本発明の皮膚外用剤は、皮膚外用剤の剤形や使用方法、用法等によりその投与量等が種々選定されるものであり、具体的に定められるものでないが、(A)成分と(B)成分の配合量やこれらの配合割合を上記範囲や後述する実施例の各剤形における配合量とし、これらを通常の方法で適用することによって、初めて本発明の効果、すなわち、今日の更なる消費者等の高い要求等に対して、しわをはじめとする皮膚の老化を防止し、滑らかでしっとりした肌を与え、安定性が更に良好な化粧用クリーム及び美容液等の皮膚化粧料等として有用なものとなる(この点については、後述する実施例等で更に詳述する)。
【0020】
【実施例】
次に、本発明を実施例及び比較例等により、さらに詳細に説明するが、本発明は下記実施例等に限定されるものではない。
【0021】
〔実施例1〜9及び比較例1〜3〕
下記表1に示すよう配合組成で、化粧用クリームを基剤に、酸化型CoA金属塩を0.5%及び/又はデホスホCoA金属塩及び/又はデホスホCoA誘導体金属塩を0.05%となるように混合した皮膚外用剤を調製した。なお、表においてデホスホCoA誘導体は、上記一般式(II)−2におけるRの部位のみを記載した。
なお、表1中の(A)成分の酸化型CoA等、(B)成分のデホスホCoA等及びデホスホCoA誘導体等以外の成分は通常の皮膚外用剤等に用いられる任意成分である(表2以下においても同様)。
【0022】
得られた実施例1〜9及び比較例1〜3の皮膚外用剤について、下記試験法により、荒れ肌改善試験、しわ改善試験、酸化型CoAの安定性試験を行った。
これらの結果を下記表1に示す。
【0023】
〔荒れ肌改善試験法〕
目周辺(目尻及び目の下)にしわを有し、乾燥により肌荒れを生じている女性120名を選び、無作為に12グループに分けた。
荒れ肌の改善度を調べるために、肌荒れを生じている下脚に被験部位4ヶ所を設定した。そして、実施例又は比較例を1日2回(朝・夜)連続2週間、被験部位に塗布させ、その肌荒れ改善度を目視し、その角層水分量を測定した(室温20℃、湿度50%、アイ・ビイ・エス社製SKICON200)。
肌荒れ改善度は、下記の評価基準に従って評価し、角層水分量は開始時と塗布2週間後の角層水分量の差(角層水分上昇量)で示した。そして、肌荒れの改善度及び角層水分量変化により総合評価を行った。
評価基準:
− :変化なし
± :やや改善
+ :改善
++:顕著に改善
【0024】
〔しわ改善試験法〕
しわの改善度を調べるために、目周辺(目尻及び目の下)のしわに本発明品または比較例を1日2回(朝・夜)、塗布した。そして、大じわ、小じわ、肌質(きめ、潤い)について評価し、実施前よりも改善等されたかのアンケート調査を行い、そのアンケート結果より、1グループ10名中の有効例数で表示した。
【0025】
〔酸化型CoAの安定性試験法〕
化粧用クリームの使用後の酸化型CoA安定性を評価するために、塗布部より回収したクリーム中に含まれている酸化型CoAの量をHPLC(高速液体クロマトグラフィー)を用いて測定し、未使用のクリーム中の酸化型CoAを100とし、塗布部位から回収したクリーム中の酸化型CoAの残存量を算出し、1グループあたりの平均値で表示した。
【0026】
【表1】
Figure 0003853097
【0027】
上記表1の結果から明らかなように、本発明の実施例1〜9の(A)成分の酸化型CoA及び/又はその塩から選ばれる少なくとも1種と、(B)成分のデホスホCoA及び/又はその塩、またはデホスホCoA誘導体及び/又はその塩から選ばれる少なくとも1種とを含有(併用)する皮膚外用剤(化粧用クリーム)は、本発明の範囲外の比較例1〜3、すなわち、上記(A)成分又は(B)成分の単独含有の皮膚外用剤に較べて、荒れ肌改善効果、しわ改善効果が高く、しかも、酸化型CoAの安定性に優れていることが判明した。
【0028】
〔実施例10〜25〕
以下に、本発明の皮膚外用剤の具体的処方例(ハンドクリーム、乳液、化粧水、アトピー性皮膚炎ローション、にきび治療剤、貼付剤)を示す。
下記表2〜7に示す配合組成で本発明となるハンドクリーム、乳液、化粧水、アトピー性皮膚炎ローション▲1▼,▲2▼、にきび治療剤、貼付剤を調製した。
【0029】
【表2】
Figure 0003853097
【0030】
【表3】
Figure 0003853097
【0031】
【表4】
Figure 0003853097
【0032】
【表5】
Figure 0003853097
【0033】
【表6】
Figure 0003853097
【0034】
【表7】
Figure 0003853097
【0035】
【発明の効果】
本発明によれば、しわをはじめとする皮膚の老化を防止し、滑らかでしっとりした肌を与え、安定性が良好な皮膚外用剤が提供される。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an external preparation for skin that prevents skin aging such as wrinkles, provides smooth and moist skin, and is useful as a skin cream and cosmetics such as cosmetic cream and beauty liquid having good stability.
[0002]
[Prior art]
Conventionally, CoA (coenzyme A, coenzyme A) and salts thereof that have no problems in skin irritation and the like, have skin cell activation, metabolism promotion, wound healing effect, etc., and are excellent in skin aging prevention effect. An external preparation for skin consisting of the above is already known (Japanese Patent Laid-Open No. 50-31051).
[0003]
However, CoA and its salts are unstable in the preparation, and there is a problem that when these are blended in cosmetics, other components such as color tone are adversely affected.
Therefore, the applicant of the present application has studied the stabilization, and the oxidized CoA synthesized by the oxidation reaction of CoA and / or its salt shows high stability in the preparation, and has a wound healing effect, fine lines, skin gloss / texture. Have been filed (Japanese Patent Laid-Open No. 2-49729, Japanese Patent No. 2781982).
[0004]
However, conventional skin external preparations containing oxidized CoA and / or salts thereof are excellent in that they exhibit stability in the preparation and have wound healing effects and improvement effects such as fine lines, skin gloss and texture. However, for today's higher demands from consumers etc., wrinkle improvement and wound healing are still not satisfactory, and when applied to human skin and put into actual use The current situation is that the stability is not yet satisfactory.
[0006]
[Problems to be solved by the invention]
In view of the above-described problems of the prior art, the present invention intends to solve this problem, and prevents the aging of the skin including wrinkles against the higher demands of today's further consumers, etc. An object of the present invention is to provide an external preparation for skin which gives smooth and moist skin and is useful as a skin cosmetic such as a cosmetic cream and a cosmetic liquid with further improved stability.
[0007]
[Means for Solving the Problems]
As a result of intensive studies on the above-mentioned conventional problems, the present inventors have used a specific type of CoA and / or a salt thereof in combination to greatly improve wrinkle improvement and wound healing and apply it to human skin. Since it was found that the stability of oxidized CoA and / or a salt thereof when actually used was greatly enhanced, and succeeded in obtaining the above-mentioned skin external preparation, the present invention was completed. is there.
That is, the external preparation for skin of the present invention comprises (A) at least one selected from oxidized CoA represented by the following general formula (I) and / or a salt thereof, and (B) the following general formula (II) -1. Or at least one selected from a dephospho CoA derivative represented by the following general formula (II) -2 and / or a salt thereof: Topical agent.
[Chemical 1]
Figure 0003853097
[Chemical 2]
Figure 0003853097
[Chemical 3]
Figure 0003853097
[R in the above general formula (II) -2 represents dephospho-CoA, 4′-phosphopantetheine, 4′-phosphopantenoylcysteine, pantethein, pantothenoylcysteine, β-arethein, cysteamine, cysteine, glutathione. Show. ]
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, embodiments of the present invention will be described in detail.
The skin external preparation of the present invention comprises (A) at least one selected from oxidized CoA represented by the following general formula (I) and / or a salt thereof, and (B) represented by the following general formula (II) -1. And / or a salt thereof, or a dephospho CoA derivative represented by the following general formula (II) -2 and / or a salt thereof: .
[Chemical 1]
Figure 0003853097
[Chemical 2]
Figure 0003853097
[Chemical 3]
Figure 0003853097
[R in the above general formula (II) -2 represents dephospho-CoA, 4′-phosphopantetheine, 4′-phosphopantenoylcysteine, pantethein, pantothenoylcysteine, β-arethein, cysteamine, cysteine, glutathione. Show. ]
[0009]
The oxidized CoA of the component (A) used in the present invention is represented by the following general formula (I), and as a salt thereof, a sodium salt, a lithium salt, or a potassium salt that forms a metal salt of a phosphate group , Metal salts such as calcium salt, magnesium salt and zinc salt.
Specific examples include disodium salt, tetrasodium salt, hexasodium salt, hexapotassium salt, tetralithium salt, hexalithium salt, dicalcium salt, dimagnesium salt, and dizinc salt of oxidized CoA.
These oxidized CoA or salts thereof can be used alone or in admixture of two or more.
[0010]
[Chemical 1]
Figure 0003853097
[0011]
The component (B) dephospho CoA used in the present invention is represented by the following general formula (II) -1, and as a salt thereof, a sodium salt, a lithium salt, or potassium that forms a metal salt of a phosphate group Examples thereof include metal salts such as salts, calcium salts, magnesium salts, and zinc salts.
Specific examples include pentasodium salt, pentapotassium salt, pentalithium salt, pentacalcium salt, pentamagnesium salt and pentazinc salt of dephospho-CoA.
These dephospho-CoA or a salt thereof can be used alone or in admixture of two or more.
[0012]
[Chemical 2]
Figure 0003853097
[0013]
Moreover, the dephospho CoA derivative of the component (B) is represented by the following general formula (II) -2, and as a salt thereof, a sodium salt, a lithium salt, or a potassium salt that forms a metal salt of a phosphate group , Metal salts such as calcium salt, magnesium salt and zinc salt.
Specifically, pentasodium salt, pentapotassium salt, pentalithium salt, pentacalcium salt, pentamagnesium salt, pentazinc salt and the like of the dephospho CoA derivative are exemplified. These dephospho CoA derivatives or salts thereof can be used alone or in admixture of two or more.
Examples of the dephospho-CoA derivative include R in the following general formula (II) -2, in addition to dephospho-CoA, 4′-phosphopantethein, 4′-phosphopantotenoylcysteine, pantethein, pantothenoylcysteine, β-arethein Cysteamine, cysteine, and glutathione, among which dephospho-CoA is particularly desirable.
[0014]
[Chemical 3]
Figure 0003853097
[0015]
In the external preparation for skin of the present invention, the content of the oxidized CoA as the component (A) is 0.001 to 5% by weight (hereinafter abbreviated as%), preferably 0. It is desirable to contain 01 to 2%.
When the content of the oxidized CoA as the component (A) is less than 0.001%, the anti-aging effect of the skin may not be obtained satisfactorily. Moreover, even if it exceeds 5%, the effect beyond it is not exhibited normally, and it is not economical.
On the other hand, the total content of the component (B) dephospho CoA and / or salt thereof, or dephospho CoA derivative and / or salt thereof is arbitrary within the range of 0.000001% to 5% with respect to the total amount of the external preparation for skin. It can be added in an amount.
When the total content of the component (B) is less than 0.000001%, a satisfactory anti-aging effect on the skin and a stability effect in the preparation of the component (A) during actual use may not be exhibited. Moreover, even if it exceeds 5%, the effect beyond it is not exhibited normally, and it is not economical.
[0016]
Further, the ratio (weight ratio) of the component (A) / component (B) is particularly preferably blended at a ratio to be each example described later.
[0017]
In addition to the above components (A) and (B), the topical skin preparation of the present invention includes oil, water, surfactant, moisturizer, plant extract, lower alcohol as long as the effects of the present invention are not impaired. , Polyhydric alcohols, higher alcohols, clay minerals, thickeners, antioxidants, chelating agents, pH adjusters, preservatives, fragrances, dyes, UV absorbers, UV scattering agents, vitamins, amino acids, water, etc. Raw materials (optional components) used for cosmetics, soap bath agents and the like can be blended.
[0018]
Examples of the external preparation for skin of the present invention include various cosmetic creams, skin milk (milky lotion), lotion (skin lotion), cosmetic liquid, pack agent, gel agent, powder, lip balm, lipstick, under makeup, foundation, sun care, Various product forms such as bath preparations, body shampoos, body rinses, soaps, cleansing foams, ointments, jellies, aerosols and the like can be mentioned, but are not limited thereto.
These products can be produced by appropriately blending the above components (A) and (B) and the above optional components in the present invention by a conventional method.
[0019]
The skin external preparation of the present invention configured as described above has various dosages and the like selected depending on the dosage form, usage method, usage and the like of the skin external preparation, and is not specifically defined ( The effects of the present invention for the first time, by applying the blending amounts of the component A) and the component (B) and blending proportions thereof in the above ranges and the dosage forms of the examples described later, and applying them in the usual manner, In other words, in response to the high demands of today's further consumers, etc., skin aging such as wrinkles is prevented, smooth and moist skin is given, and cosmetic creams and serums with even better stability, etc. (This will be described in more detail in Examples and the like to be described later).
[0020]
【Example】
EXAMPLES Next, although an Example and a comparative example demonstrate this invention further in detail, this invention is not limited to the following Example etc.
[0021]
[Examples 1 to 9 and Comparative Examples 1 to 3]
As shown in Table 1 below, the cosmetic cream is used as a base, the oxidized CoA metal salt is 0.5% and / or the dephospho CoA metal salt and / or the dephospho CoA derivative metal salt is 0.05%. Thus, the skin external preparation mixed was prepared. In the table, for the dephospho CoA derivative, only the R site in the general formula (II) -2 is shown.
In Table 1, components other than the oxidized CoA of the component (A), the dephospho CoA of the component (B), the dephospho CoA derivative and the like are optional components used in normal skin external preparations and the like (Table 2 and below). The same applies to the above).
[0022]
About the obtained skin external preparation of Examples 1-9 and Comparative Examples 1-3, the rough skin improvement test, the wrinkle improvement test, and the stability test of oxidation type CoA were done by the following test method.
These results are shown in Table 1 below.
[0023]
[Rough skin improvement test method]
Twelve women who had wrinkles around the eyes (the corners of the eyes and under the eyes) and had rough skin due to dryness were randomly selected and divided into 12 groups.
In order to examine the improvement degree of rough skin, four test sites were set on the lower leg where rough skin was generated. Then, Examples or Comparative Examples were applied to the test site twice a day (morning and night) for 2 consecutive weeks, and the degree of improvement in rough skin was visually observed, and the stratum corneum moisture content was measured (room temperature 20 ° C., humidity 50). %, SKICON200 manufactured by IBS Inc.).
The degree of improvement in rough skin was evaluated according to the following evaluation criteria, and the stratum corneum moisture content was shown as the difference between the stratum corneum moisture content at the start and two weeks after application (corne stratum moisture increase amount). And comprehensive evaluation was performed by the improvement degree of rough skin, and a stratum corneum moisture content change.
Evaluation criteria:
−: No change ±: Slightly improved +: Improved ++: Remarkably improved
[Wrinkle improvement test method]
In order to examine the degree of improvement of wrinkles, the product of the present invention or a comparative example was applied twice a day (morning and night) to the wrinkles around the eyes (the corners of the eyes and under the eyes). And it evaluated about fine wrinkles, fine wrinkles, and skin quality (texture, moisture), conducted a questionnaire survey to see if it was improved compared to before implementation, and displayed the number of effective cases in 10 people per group from the questionnaire results.
[0025]
[Stability test method for oxidized CoA]
In order to evaluate the stability of oxidized CoA after the use of the cosmetic cream, the amount of oxidized CoA contained in the cream collected from the coated part was measured using HPLC (high performance liquid chromatography). The remaining amount of oxidized CoA in the cream recovered from the application site was calculated with the oxidized CoA in the cream used being 100, and displayed as an average value per group.
[0026]
[Table 1]
Figure 0003853097
[0027]
As is clear from the results in Table 1 above, at least one selected from the oxidized CoA and / or salt thereof as component (A) in Examples 1 to 9 of the present invention, and dephospho CoA as component (B) and / or Or a salt thereof, or a skin external preparation (cosmetic cream) containing (in combination with) at least one selected from a dephospho-CoA derivative and / or a salt thereof, Comparative Examples 1 to 3 outside the scope of the present invention, It was found that compared with the above-mentioned skin preparation for external use containing only the component (A) or the component (B), the rough skin improvement effect and the wrinkle improvement effect are high, and the stability of the oxidized CoA is excellent.
[0028]
[Examples 10 to 25]
The specific formulation example (hand cream, emulsion, lotion, atopic dermatitis lotion, acne treatment agent, patch) of the external preparation for skin of the present invention is shown below.
Hand creams, emulsions, lotions, atopic dermatitis lotions (1), (2), acne treatment agents, and patches of the present invention were prepared with the composition shown in Tables 2 to 7 below.
[0029]
[Table 2]
Figure 0003853097
[0030]
[Table 3]
Figure 0003853097
[0031]
[Table 4]
Figure 0003853097
[0032]
[Table 5]
Figure 0003853097
[0033]
[Table 6]
Figure 0003853097
[0034]
[Table 7]
Figure 0003853097
[0035]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, the aging of skin including wrinkles is prevented, the smooth and moist skin is given, and the skin external preparation with favorable stability is provided.

Claims (1)

(A)下記一般式(I)で表される酸化型CoA及び/又はその塩から選ばれる少なくとも1種と、(B)下記一般式(II)−1で表されるデホスホCoA及び/又はその塩、または、下記一般式(II)−2で表されるデホスホCoA誘導体及び/又はその塩から選ばれる少なくとも1種とを含有することを特徴とする皮膚外用剤。
Figure 0003853097
Figure 0003853097
Figure 0003853097
〔上記一般式(II)−2中のRは、デホスホCoA、4’−ホスホパンテテイン、4’−ホスホパントテノイルシステイン、パンテテイン、パントテノイルシステイン、β-アレテイン、システアミン、システイン、グルタチオンを示す。〕」
(A) at least one selected from oxidized CoA represented by the following general formula (I) and / or a salt thereof; and (B) dephospho CoA represented by the following general formula (II) -1 and / or the same A skin external preparation characterized by containing a salt or a dephospho CoA derivative represented by the following general formula (II) -2 and / or a salt thereof.
Figure 0003853097
Figure 0003853097
Figure 0003853097
[R in the above general formula (II) -2 is dephospho CoA, 4′-phosphopantethein, 4′-phosphopantotenoylcysteine, pantethein, pantothenoylcysteine, β-arethein, cysteamine, cysteine, glutathione. Show. ]
JP37114298A 1998-12-25 1998-12-25 Topical skin preparation Expired - Fee Related JP3853097B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP37114298A JP3853097B2 (en) 1998-12-25 1998-12-25 Topical skin preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP37114298A JP3853097B2 (en) 1998-12-25 1998-12-25 Topical skin preparation

Publications (2)

Publication Number Publication Date
JP2000191495A JP2000191495A (en) 2000-07-11
JP3853097B2 true JP3853097B2 (en) 2006-12-06

Family

ID=18498219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP37114298A Expired - Fee Related JP3853097B2 (en) 1998-12-25 1998-12-25 Topical skin preparation

Country Status (1)

Country Link
JP (1) JP3853097B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3994257B2 (en) * 2000-11-22 2007-10-17 大塚製薬株式会社 O / W type emulsified composition and method for preparing the same

Also Published As

Publication number Publication date
JP2000191495A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
CA1325599C (en) Cosmetic composition
US4474763A (en) Skin preparation
JP3503884B2 (en) Cosmetics
JPH08501553A (en) Skin conditioning composition, its application and manufacture
JP3908126B2 (en) Epidermal keratinization normalizing agent and skin external preparation containing the same
JPH08283139A (en) Dermal preparation for external use
JP3426436B2 (en) Skin cosmetics
JPS61183206A (en) Cell-activating agent
JPH03153609A (en) Skin-beautifying cosmetic
JP5455292B2 (en) Skin external composition
JP2953529B2 (en) New cosmetics
JP3853097B2 (en) Topical skin preparation
JPH0521085B2 (en)
JPS60116618A (en) Cosmetic
JPH10265323A (en) Skin preparation for external use
JPH11180851A (en) Skin cosmetic
JPS6281307A (en) Skin cosmetic
JPS62226910A (en) Skin cosmetic
JPH0678223B2 (en) Skin cosmetics
JPH03291207A (en) Dermatic agent for external use
JPH0363207A (en) Skin cosmetic
JP2003277251A (en) New beautifying and whitening cosmetic
JPH0692833A (en) Skin external agent
JPS617206A (en) Cell activator
JPH0788294B2 (en) Cosmetics

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050415

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20050415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060523

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060905

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090915

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100915

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100915

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110915

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110915

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120915

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130915

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees